Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Gro...

Autores
Rapoport, Bernardo L.; Shannon, Vickie R.; Cooksley, Tim; Johnson, Douglas B.; Anderson, Lindsay; Blidner, Ada Gabriela; Tintinger, Gregory R.; Anderson, Ronald
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and a variety of solid tumors, either as single agents or in combination with other anticancer modalities. Additional indications are continuing to evolve. Checkpoint inhibitors are associated with less toxicity when compared to chemotherapy. These agents enhance the antitumor immune response and produce side- effects known as immune-related adverse events (irAEs). Although the incidence of immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) is relatively low, this complication is likely to cause the delay or cessation of immunotherapy and, in severe cases, may be associated with treatment-related mortality. The primary mechanism of ICI-Pneumonitis remains unclear, but it is believed to be associated with the immune dysregulation caused by ICIs. The development of irAEs may be related to increased T cell activity against cross-antigens expressed in tumor and normal tissues. Treatment with ICIs is associated with an increased number of activated alveolar T cells and reduced activity of the anti-inflammatory Treg phenotype, leading to dysregulation of T cell activity. This review discusses the pathogenesis of alveolar pneumonitis and the incidence, diagnosis, and clinical management of pulmonary toxicity, as well as the pulmonary complications of ICIs, either as monotherapy or in combination with other anticancer modalities, such as thoracic radiotherapy.
Fil: Rapoport, Bernardo L.. University of Pretoria. Faculty of Health Sciences; Sudáfrica. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. The Medical Oncology Centre of Rosebank; Sudáfrica
Fil: Shannon, Vickie R.. University of Texas; Estados Unidos
Fil: Cooksley, Tim. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Manchester; Reino Unido
Fil: Johnson, Douglas B.. Vanderbilt University; Estados Unidos
Fil: Anderson, Lindsay. University of Pretoria. Faculty of Health Sciences; Sudáfrica
Fil: Blidner, Ada Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Tintinger, Gregory R.. University of Pretoria. Faculty of Health Sciences; Sudáfrica
Fil: Anderson, Ronald. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Pretoria. Faculty of Health Sciences; Sudáfrica
Materia
ANTI-CTLA-4 ANTIBODIES
ANTI-PDL-1 MONOCLONAL ANTIBODIES
IMMUNE CHECKPOINT INHIBITORS
IMMUNE RELATED ADVERSE EFFECTS
PNEUMONITIS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/163188

id CONICETDig_b04596928d6c3d7b9fa87c9c194ab3b7
oai_identifier_str oai:ri.conicet.gov.ar:11336/163188
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in CancerRapoport, Bernardo L.Shannon, Vickie R.Cooksley, TimJohnson, Douglas B.Anderson, LindsayBlidner, Ada GabrielaTintinger, Gregory R.Anderson, RonaldANTI-CTLA-4 ANTIBODIESANTI-PDL-1 MONOCLONAL ANTIBODIESIMMUNE CHECKPOINT INHIBITORSIMMUNE RELATED ADVERSE EFFECTSPNEUMONITIShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and a variety of solid tumors, either as single agents or in combination with other anticancer modalities. Additional indications are continuing to evolve. Checkpoint inhibitors are associated with less toxicity when compared to chemotherapy. These agents enhance the antitumor immune response and produce side- effects known as immune-related adverse events (irAEs). Although the incidence of immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) is relatively low, this complication is likely to cause the delay or cessation of immunotherapy and, in severe cases, may be associated with treatment-related mortality. The primary mechanism of ICI-Pneumonitis remains unclear, but it is believed to be associated with the immune dysregulation caused by ICIs. The development of irAEs may be related to increased T cell activity against cross-antigens expressed in tumor and normal tissues. Treatment with ICIs is associated with an increased number of activated alveolar T cells and reduced activity of the anti-inflammatory Treg phenotype, leading to dysregulation of T cell activity. This review discusses the pathogenesis of alveolar pneumonitis and the incidence, diagnosis, and clinical management of pulmonary toxicity, as well as the pulmonary complications of ICIs, either as monotherapy or in combination with other anticancer modalities, such as thoracic radiotherapy.Fil: Rapoport, Bernardo L.. University of Pretoria. Faculty of Health Sciences; Sudáfrica. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. The Medical Oncology Centre of Rosebank; SudáfricaFil: Shannon, Vickie R.. University of Texas; Estados UnidosFil: Cooksley, Tim. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Manchester; Reino UnidoFil: Johnson, Douglas B.. Vanderbilt University; Estados UnidosFil: Anderson, Lindsay. University of Pretoria. Faculty of Health Sciences; SudáfricaFil: Blidner, Ada Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Tintinger, Gregory R.. University of Pretoria. Faculty of Health Sciences; SudáfricaFil: Anderson, Ronald. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Pretoria. Faculty of Health Sciences; SudáfricaFrontiers Media2021-10-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/163188Rapoport, Bernardo L.; Shannon, Vickie R.; Cooksley, Tim; Johnson, Douglas B.; Anderson, Lindsay; et al.; Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer; Frontiers Media; Frontiers in Pharmacology; 12; 743582; 5-10-2021; 1-171663-9812CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fphar.2021.743582/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fphar.2021.743582info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:12:10Zoai:ri.conicet.gov.ar:11336/163188instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:12:11.124CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
title Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
spellingShingle Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
Rapoport, Bernardo L.
ANTI-CTLA-4 ANTIBODIES
ANTI-PDL-1 MONOCLONAL ANTIBODIES
IMMUNE CHECKPOINT INHIBITORS
IMMUNE RELATED ADVERSE EFFECTS
PNEUMONITIS
title_short Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
title_full Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
title_fullStr Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
title_full_unstemmed Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
title_sort Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
dc.creator.none.fl_str_mv Rapoport, Bernardo L.
Shannon, Vickie R.
Cooksley, Tim
Johnson, Douglas B.
Anderson, Lindsay
Blidner, Ada Gabriela
Tintinger, Gregory R.
Anderson, Ronald
author Rapoport, Bernardo L.
author_facet Rapoport, Bernardo L.
Shannon, Vickie R.
Cooksley, Tim
Johnson, Douglas B.
Anderson, Lindsay
Blidner, Ada Gabriela
Tintinger, Gregory R.
Anderson, Ronald
author_role author
author2 Shannon, Vickie R.
Cooksley, Tim
Johnson, Douglas B.
Anderson, Lindsay
Blidner, Ada Gabriela
Tintinger, Gregory R.
Anderson, Ronald
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ANTI-CTLA-4 ANTIBODIES
ANTI-PDL-1 MONOCLONAL ANTIBODIES
IMMUNE CHECKPOINT INHIBITORS
IMMUNE RELATED ADVERSE EFFECTS
PNEUMONITIS
topic ANTI-CTLA-4 ANTIBODIES
ANTI-PDL-1 MONOCLONAL ANTIBODIES
IMMUNE CHECKPOINT INHIBITORS
IMMUNE RELATED ADVERSE EFFECTS
PNEUMONITIS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and a variety of solid tumors, either as single agents or in combination with other anticancer modalities. Additional indications are continuing to evolve. Checkpoint inhibitors are associated with less toxicity when compared to chemotherapy. These agents enhance the antitumor immune response and produce side- effects known as immune-related adverse events (irAEs). Although the incidence of immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) is relatively low, this complication is likely to cause the delay or cessation of immunotherapy and, in severe cases, may be associated with treatment-related mortality. The primary mechanism of ICI-Pneumonitis remains unclear, but it is believed to be associated with the immune dysregulation caused by ICIs. The development of irAEs may be related to increased T cell activity against cross-antigens expressed in tumor and normal tissues. Treatment with ICIs is associated with an increased number of activated alveolar T cells and reduced activity of the anti-inflammatory Treg phenotype, leading to dysregulation of T cell activity. This review discusses the pathogenesis of alveolar pneumonitis and the incidence, diagnosis, and clinical management of pulmonary toxicity, as well as the pulmonary complications of ICIs, either as monotherapy or in combination with other anticancer modalities, such as thoracic radiotherapy.
Fil: Rapoport, Bernardo L.. University of Pretoria. Faculty of Health Sciences; Sudáfrica. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. The Medical Oncology Centre of Rosebank; Sudáfrica
Fil: Shannon, Vickie R.. University of Texas; Estados Unidos
Fil: Cooksley, Tim. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Manchester; Reino Unido
Fil: Johnson, Douglas B.. Vanderbilt University; Estados Unidos
Fil: Anderson, Lindsay. University of Pretoria. Faculty of Health Sciences; Sudáfrica
Fil: Blidner, Ada Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Tintinger, Gregory R.. University of Pretoria. Faculty of Health Sciences; Sudáfrica
Fil: Anderson, Ronald. Multinational Association of Supportive Care in Cancer. Immuno Oncology Subgroup of the Neutropenia, Infection and Myelosuppresion Study Group; Reino Unido. University of Pretoria. Faculty of Health Sciences; Sudáfrica
description The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and a variety of solid tumors, either as single agents or in combination with other anticancer modalities. Additional indications are continuing to evolve. Checkpoint inhibitors are associated with less toxicity when compared to chemotherapy. These agents enhance the antitumor immune response and produce side- effects known as immune-related adverse events (irAEs). Although the incidence of immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) is relatively low, this complication is likely to cause the delay or cessation of immunotherapy and, in severe cases, may be associated with treatment-related mortality. The primary mechanism of ICI-Pneumonitis remains unclear, but it is believed to be associated with the immune dysregulation caused by ICIs. The development of irAEs may be related to increased T cell activity against cross-antigens expressed in tumor and normal tissues. Treatment with ICIs is associated with an increased number of activated alveolar T cells and reduced activity of the anti-inflammatory Treg phenotype, leading to dysregulation of T cell activity. This review discusses the pathogenesis of alveolar pneumonitis and the incidence, diagnosis, and clinical management of pulmonary toxicity, as well as the pulmonary complications of ICIs, either as monotherapy or in combination with other anticancer modalities, such as thoracic radiotherapy.
publishDate 2021
dc.date.none.fl_str_mv 2021-10-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/163188
Rapoport, Bernardo L.; Shannon, Vickie R.; Cooksley, Tim; Johnson, Douglas B.; Anderson, Lindsay; et al.; Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer; Frontiers Media; Frontiers in Pharmacology; 12; 743582; 5-10-2021; 1-17
1663-9812
CONICET Digital
CONICET
url http://hdl.handle.net/11336/163188
identifier_str_mv Rapoport, Bernardo L.; Shannon, Vickie R.; Cooksley, Tim; Johnson, Douglas B.; Anderson, Lindsay; et al.; Pulmonary toxicities associated with the use of immune checkpoint inhibitors: an update from the immuno-oncology subgroup of the neutropenia, infection & myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer; Frontiers Media; Frontiers in Pharmacology; 12; 743582; 5-10-2021; 1-17
1663-9812
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fphar.2021.743582/full
info:eu-repo/semantics/altIdentifier/doi/10.3389/fphar.2021.743582
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614026666967040
score 13.070432